Trevi Therapeutics Past Earnings Performance
Past criteria checks 0/6
Trevi Therapeutics's earnings have been declining at an average annual rate of -1.6%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
-1.6%
Earnings growth rate
88.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -35.2% |
| Net Margin | n/a |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Trevi Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -29 | 10 | 24 |
| 30 Sep 23 | 0 | -27 | 10 | 21 |
| 30 Jun 23 | 0 | -27 | 10 | 21 |
| 31 Mar 23 | 0 | -28 | 10 | 20 |
| 31 Dec 22 | 0 | -29 | 10 | 20 |
| 30 Sep 22 | 0 | -32 | 10 | 22 |
| 30 Jun 22 | 0 | -31 | 9 | 21 |
| 31 Mar 22 | 0 | -33 | 9 | 22 |
| 31 Dec 21 | 0 | -34 | 9 | 23 |
| 30 Sep 21 | 0 | -35 | 10 | 23 |
| 30 Jun 21 | 0 | -35 | 10 | 23 |
| 31 Mar 21 | 0 | -33 | 10 | 22 |
| 31 Dec 20 | 0 | -33 | 10 | 22 |
| 30 Sep 20 | 0 | -30 | 9 | 21 |
| 30 Jun 20 | 0 | -30 | 9 | 21 |
| 31 Mar 20 | 0 | -29 | 8 | 22 |
| 31 Dec 19 | 0 | -27 | 7 | 19 |
| 30 Sep 19 | 0 | -28 | 7 | 19 |
| 30 Jun 19 | 0 | -27 | 6 | 17 |
| 31 Mar 19 | 0 | -27 | 5 | 15 |
| 31 Dec 18 | 0 | -26 | 4 | 14 |
| 30 Sep 18 | 0 | -22 | 4 | 11 |
| 31 Dec 17 | 0 | -13 | 2 | 6 |
Quality Earnings: TRVI is currently unprofitable.
Growing Profit Margin: TRVI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRVI is unprofitable, and losses have increased over the past 5 years at a rate of 1.6% per year.
Accelerating Growth: Unable to compare TRVI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRVI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: TRVI has a negative Return on Equity (-35.21%), as it is currently unprofitable.